Compare TIMB & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TIMB | ICLR |
|---|---|---|
| Founded | 1998 | 1990 |
| Country | Brazil | Ireland |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 9.3B |
| IPO Year | 2020 | 2001 |
| Metric | TIMB | ICLR |
|---|---|---|
| Price | $23.28 | $119.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 13 |
| Target Price | $25.10 | ★ $178.62 |
| AVG Volume (30 Days) | 406.2K | ★ 1.4M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.88% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.47 | N/A |
| Revenue Next Year | $4.80 | N/A |
| P/E Ratio | $15.81 | ★ $12.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.64 | $66.57 |
| 52 Week High | $28.22 | $211.00 |
| Indicator | TIMB | ICLR |
|---|---|---|
| Relative Strength Index (RSI) | 35.67 | 55.08 |
| Support Level | $22.29 | $99.11 |
| Resistance Level | $23.98 | $193.87 |
| Average True Range (ATR) | 0.68 | 6.57 |
| MACD | -0.32 | 1.24 |
| Stochastic Oscillator | 2.42 | 65.68 |
TIM, which is 67%-owned by Telecom Italia, is the third-largest wireless carrier in Brazil, with 62 million subscribers, equal to about 23% of the market. The firm owns 49% of I-Systems, an infrastructure partnership that is expanding its network footprint across Brazil. I-Systems can provide broadband service to about 8 million locations, including 6.5 million with fiber, equal to 10%-15% of the country. TIM leases capacity on the venture's network to serve retail broadband customers under the UltraFibra brand, but it has agreed to buy out its joint venture partner in 2026 and will take full ownership of these assets. TIM also resells fiber network access from other providers.
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.